| Metric | Current Period | Prior Year Period | YoY |
|---|---|---|---|
| Revenue / Net Sales | ¥297.2B | ¥240.9B | +23.3% |
| Operating Income / Operating Profit | ¥44.0B | ¥23.1B | +90.8% |
| Ordinary Income | ¥42.6B | ¥22.1B | +92.9% |
| Net Income / Net Profit | ¥7.1B | ¥12.9B | -44.6% |
| ROE | 1.4% | 2.7% | - |
2026 FY Q2 results: Revenue ¥297.2B (YoY +¥56.2B +23.3%), Operating Income ¥44.0B (YoY +¥20.9B +90.8%), Ordinary Income ¥42.6B (YoY +¥20.5B +92.9%), Net Income ¥7.1B (YoY -¥5.7B -44.6%). Operating-stage profitability improved substantially, but Net Income declined YoY due to the recording of special losses ¥35.8B including an investment securities valuation loss ¥35.2B. Operating margin improved to 14.8% from 9.6% a year earlier (+5.2pt), and gross margin also rose to 41.5% (prior 40.9%). SG&A ratio fell to 26.7% (prior 31.5%), and operating leverage worked favorably against revenue growth. Progress against full-year guidance is Revenue 50.1%, Operating Income 71.9%, Ordinary Income 72.5% — core earnings are on track, but Net Income lags at 3.2% due to the one-off loss.
[Revenue] Revenue was ¥297.2B (YoY +23.3%) with robust top-line growth. The Group operates a single Pharmaceuticals Business segment and does not disclose segment breakdowns, but short-term advances received (deferred revenue) increased from ¥0.4B to ¥1.3B year-on-year, indicating steady order trends. Gross margin improved to 41.5% from an estimated 41.0% a year earlier (+0.5pt), suggesting product-mix improvement and effective cost control. Cost of goods sold increased to ¥173.8B (prior ¥142.1B, +22.3%), but the revenue growth outpaced COGS increases.
[Profitability] Operating Income was ¥44.0B (YoY +90.8%), a large rise. SG&A was ¥79.3B (prior ¥75.8B, +4.5%) but SG&A ratio fell to 26.7% (prior 31.5%, -4.8pt) due to revenue growth, so operating leverage contributed. Ordinary Income was ¥42.6B (YoY +92.9%), similarly strong. Non-operating income was ¥1.4B and non-operating expenses were ¥2.8B; interest expense was ¥1.9B (prior ¥1.4B), slightly higher but with minor impact on ordinary-stage results. Pretax income was ¥6.8B (prior ¥17.5B, -61.0%) mainly due to special losses of ¥35.8B (prior ¥4.6B). Breakdown: investment securities valuation loss ¥35.2B, impairment losses ¥3.9B, disaster losses ¥0.0B, etc. Income taxes were -¥0.3B (effective tax rate -4.2%), with an increase in deferred tax assets of ¥13.3B exceeding current tax expense of ¥12.9B, producing a large positive tax effect. As a result Net Income was ¥7.1B (YoY -44.6%). Conclusion: strong revenue-driven operating and ordinary profit growth, but Net Income declined due to temporary special losses.
[Profitability] Operating margin improved to 14.8% (prior 9.6%, +5.2pt), and gross margin rose to 41.5% (prior est. 41.0%). Operating leverage and product-mix improvement contributed. Net margin fell to 2.4% (prior 5.3%), mainly due to recording special losses ¥35.8B, while recurring earning power strengthened. ROE is 1.4% (prior est. 2.7%) and remains low, reflecting temporary compression of Net Income. [Cash Quality] Operating Cash Flow (OCF) was ¥40.6B (prior ¥21.3B, +90.5%), a large increase. OCF/Net Income is 5.7x, high partly due to non-cash adjustment for the investment securities valuation loss. OCF/EBITDA is 0.63x (EBITDA ¥64.5B = Operating Income ¥44.0B + Depreciation ¥20.6B), which is low. Working capital absorbed cash: Inventory -¥31.3B (DIO 514 days) and Accounts Receivable ¥7.8B (DSO 171 days), resulting in CCC 579 days, extended. Free Cash Flow was ¥20.8B, sufficient to cover dividends ¥6.2B and CapEx ¥9.1B. [Investment Efficiency] Total asset turnover is 0.30x, standard. CapEx/Depreciation is 0.44x, low and potentially below maintenance level, posing a challenge for medium-term growth investment capacity. [Solvency] Equity Ratio is 52.4% (prior 50.2%), improved. Current ratio 168.2%, quick ratio 145.6% — liquidity is healthy. Debt-to-equity ratio is 0.91x, Debt/Capital 29.9% — moderate, but Debt/EBITDA is 3.39x, somewhat high. Short-term borrowings ¥153.0B comprise the bulk of interest-bearing debt and short-term debt ratio is 69.9%, creating a pronounced maturity mismatch and refinancing risk. Interest coverage is 23.3x, indicating strong interest-paying capacity.
Operating Cash Flow was ¥40.6B (prior ¥21.3B, +90.5%), with operating cash subtotal (before working capital changes) of ¥52.9B (prior ¥39.2B). Working capital deteriorated sharply: inventories -¥31.3B (inventory increase ¥73.0B, prior ¥65.7B) absorbed cash. Accounts receivable improved by +¥7.8B, but payables contributed only +¥4.0B. Corporate tax payments were -¥10.4B (prior -¥16.5B), decreasing. Investing CF was -¥19.8B, led by CapEx -¥9.1B (prior -¥6.7B) and intangible asset investment -¥9.9B (prior -¥17.3B). Investment pace eased versus prior year, but CapEx is only 0.44x depreciation ¥20.6B, so securing investment capacity remains an issue. Financing CF was +¥13.9B: long-term borrowings raised +¥90.0B exceeded short-term borrowings repayments -¥68.2B, resulting in net increase in funding. Dividend payments were -¥6.2B. Free Cash Flow was ¥20.8B, covering dividends and investment, and cash & deposits increased by ¥36.4B to ¥108.9B (prior ¥72.5B). Improving working capital efficiency and normalizing investment levels are key to strengthening future cash generation.
The decline in Net Income this period is mainly due to special losses ¥35.8B (including investment securities valuation loss ¥35.2B); recurring earning power is strengthened as reflected by Operating Margin 14.8%. Non-operating items are minor: non-operating income ¥1.4B, non-operating expenses ¥2.8B relative to sales. The gap between Ordinary Income ¥42.6B and Net Income ¥7.1B is large, but driven by one-off special losses; pretax income was ¥6.8B while income taxes were -¥0.3B and deferred tax asset increases ¥13.3B produced a sizable positive tax effect. Accrual ratio is -3.4% ((Net Income ¥7.1B – Operating CF ¥40.6B) ÷ Total Assets ¥979.4B), indicating good cash backing of profits. However, OCF/EBITDA at 0.63x is low and working capital deterioration (inventory -¥31.3B) impedes cash conversion. Comprehensive income was ¥17.6B, exceeding Net Income ¥7.1B; components include foreign currency translation adjustments ¥5.5B and valuation differences on securities ¥5.0B, indicating some temporary valuation gains. Recurring quality of earnings is high, but sustained cash generation requires improvement in working capital efficiency.
Full-year guidance (Revenue ¥592.5B, Operating Income ¥61.2B, Ordinary Income ¥58.8B, Net Income ¥22.4B) progress ratios: Revenue 50.1%, Operating Income 71.9%, Ordinary Income 72.5%, Net Income 3.2%. Operating and ordinary results substantially exceed standard half-year progress (50% at Q2), highlighting a strong first half. Net Income lags materially due to special losses ¥35.8B; achieving full-year Net Income assumes no repeat of one-off losses in H2. Guidance plans YoY growth of Revenue +14.7%, Operating Income +22.6%, Ordinary Income +31.9%; if operating-stage profitability improvements persist, Operating and Ordinary results could beat guidance. Forecast EPS for Net Income is ¥91.54; H1 realized EPS is ¥28.75 (31.4% progress), so H2 recovery in earnings is critical. No revisions to earnings or dividend guidance were made this quarter.
Q2 dividend was ¥23, with full-year dividend forecast ¥26.0 including year-end. H1 EPS ¥28.75 yields a payout ratio of 85.6%, high largely because Net Income was temporarily compressed by special losses. Total dividends relative to Free Cash Flow: dividends approximately ¥6.2B (Total dividends = ¥23 × approx. 26.8 million shares ÷ 2, estimate) with FCF ¥20.8B, giving FCF coverage of 3.4x — ample room. Cash balance increased to ¥108.9B (prior ¥72.5B), maintaining liquidity. If one-off losses drop out and Net Income recovers to forecast ¥22.4B, payout ratio would normalize to 28.4% (¥26 ÷ ¥91.54). Short-term payout ratio is high, but funding capacity is sufficient and dividend sustainability is secured. No buyback announcement; shareholder returns are dividend-centric.
Working capital inefficiency risk: Inventory days 514, Accounts Receivable days 171, CCC 579 days — elongated. Inventory increased +11.1% from ¥65.7B to ¥73.0B. Risks include obsolescence from inventory stagnation and counterparty credit risk from prolonged receivables, which could reduce operating cash generation and strain liquidity. Normalizing working capital is key to sustainable cash generation.
Refinancing risk from high short-term debt reliance: Short-term borrowings ¥153.0B are the main component of interest-bearing debt and short-term debt ratio is 69.9%. Cash ¥108.9B cannot cover total short-term debt, highlighting a maturity mismatch. Debt/EBITDA is 3.39x and borrowing dependence is material; interest rate hikes or financing institution responses could pressure liquidity.
Medium-term growth risk from suppressed investment levels: CapEx/Depreciation is 0.44x and intangible investment fell from -¥17.3B to -¥9.9B. Investment may fall below maintenance levels, risking insufficient accumulation of production capacity and R&D assets, which could impair competitiveness. In pharmaceuticals, maintaining R&D investment ratios is important; monitor future investment policy.
Profitability & Returns
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Operating Margin | 14.8% | – | – |
| Net Margin | 2.4% | – | – |
Operating margin improved markedly to 14.8% from 9.6% a year earlier. Net margin is low at 2.4% due to special losses, but ordinary-stage profitability is healthy.
Growth & Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth Rate (YoY) | 23.3% | – | – |
Revenue growth rate 23.3% is high.
※ Source: Company compilation
Operating-stage profitability improved substantially: Operating Margin 14.8% (prior 9.6%), Gross Margin 41.5% (prior est. 41.0%). Decline in SG&A ratio and operating leverage effects are clear, with progress versus full-year guidance showing Operating Income 71.9% and Ordinary Income 72.5% — indicating upside potential. Product-mix improvement and SG&A efficiency have driven structural improvements in core earnings power.
Net Income fell YoY -44.6% due to special losses ¥35.8B (including investment securities valuation loss ¥35.2B), but these are one-off. Ordinary Income rose +92.9%; absent repeated one-offs in H2, Net Income could recover substantially. Net Income progress versus full-year guidance is 3.2%, so H2 performance is critical to full-year achievement.
Working capital deterioration (CCC 579 days, Inventory +11.1%) and suppressed investment (CapEx/Depreciation 0.44x) are medium-term concerns. Short-term debt ratio 69.9% and reliance on short-term borrowings are high; improving debt maturity profile should be prioritized. Interest coverage 23.3x shows debt service capacity, but Debt/EBITDA 3.39x indicates somewhat elevated leverage — normalizing inventory/receivables and revising investment levels are prerequisites for sustainable growth.
This report was auto-generated by AI analyzing XBRL financial statement data. It does not constitute a recommendation to invest in any specific security. Industry benchmarks are company-compiled reference information based on public financial data. Investment decisions are your responsibility; consult a professional advisor as needed.